Dr. Agarwal Discusses Results of KEYNOTE-426 in mRCC

Video

In Partnership With:

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma (mRCC).

For the phase III study presented at the 2019 Genitourinary Cancers Symposium, investigators randomized patients to receive either pembrolizumab (Keytruda) plus axitinib (Inlyta) or sunitinib (Sutent). Progression-free survival was clearly superior with the immunotherapy/TKI combination compared with the standard TKI alone, Agarwal says. Objective response rates were 59% with the combination versus 36% with sunitinib. Further, the checkpoint inhibitor and TKI combination significantly increased overall survival in these patients.

Based on this data, pembrolizumab plus axitinib seems to be a promising new option for patients with mRCC, Agarwal notes, although the complete response rates with the combination were lower than those seen the FDA-approved combination of nivolumab (Opdivo) and ipilimumab (Yervoy)—5% versus 11% in favor of the PD-1/CTLA-4 inhibitor combination. Agarwal says this is the only qualm he has with pembrolizumab plus axitinib.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute